The role of maintenance therapy in disseminated testicular cancer.
The role of maintenance therapy in disseminated testicular cancer.
复制标题
维持治疗在播散性睾丸癌中的作用。
DOI：
10.1056/nejm198109243051303
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
Greco,FA
中科院分区：
文献类型：
--
作者：
Einhorn,LH;Williams,SD;Troner,M;Birch,R;Greco,FA
我们进行了一项前瞻性研究，探讨在化疗诱导完全缓解或化疗细胞减灭术后手术切除残留畸胎瘤的播散性睾丸癌中维持治疗的价值。一组171例患者被随机分配到顺铂，长春碱，博莱霉素，或这些药物加阿霉素组成的治疗。这两种诱导方案之间无明显差异。113例患者（66%）达到完全缓解，19例（11%）通过手术切除残余肿瘤而无病。在171例开始治疗的患者中，113例有资格接受长春碱维持剂量（58例患者）或缓解诱导治疗后不再接受进一步治疗（55例患者）。长春碱维持治疗期间复发率为9%，无维持治疗复发率为7%;总体复发率为8%（113例中有9例）。我们的数据表明，维持治疗是不必要的播散性睾丸癌。（《新英格兰医学杂志》，1981年; 305：727- 731）
We conducted a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer. (N Engl J Med. 1981; 305:727–31.)